MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

This trial is testing whether a new antibody drug called MIL62 combined with lenalidomide (a standard immune-modulating drug) is better than lenalidomide alone for treating follicular lymphoma (a slow-growing blood cancer) that has stopped responding to rituximab, the usual first-line antibody treatment. **You may be eligible if...** - You are 18 years or older - You have follicular lymphoma (grade 1, 2, or 3a) confirmed by biopsy, with the CD20 protein on the cancer cells - Your lymphoma stopped responding to rituximab (rituximab-refractory) - Your cancer is measurable on scans - You are in reasonably good health and your blood counts and organs are adequate - Your expected survival is more than 5 years **You may NOT be eligible if...** - You have already tried lenalidomide and your cancer did not respond to it - Your lymphoma has spread to the brain or spinal fluid - You have progressive multifocal leukoencephalopathy (a serious brain infection) - You have received other antibody treatments (other than rituximab) for this cancer Talk to your doctor to see if this trial is right for you.